Feb 16 (Reuters) - Alexion Pharmaceuticals Inc ALXN.O :
* Pan Canadian pharmaceutical alliance-ended negotiations with Alexion for
listing of soliris for the treatment of atypical hemolytic uremic syndrome
* Pan Canadian pharmaceutical alliance-negotiations ended with manufacturer as
Alexion and the pcpa could not reach an agreement on funding criteria
* Pan Canadian pharmaceutical alliance - there was also a disagreement of
financial terms
* Pan Canadian pharmaceutical alliance - patented medicine prices review board
is considering whether the price being charged for soliris is too high
* Pan Canadian pharmaceutical alliance-willing to re-engage in talks with
Alexion on soliris if manufacturer able to address clinical,financial
concerns
Source text for Eikon
Further company coverage ALXN.O